These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 3547618)

  • 41. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W; Stieglitz M; Baars B; Opferkuch W
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
    Ridgway GL; Mumtaz G; Gabriel FG; Oriel JD
    Eur J Clin Microbiol; 1984 Aug; 3(4):344-6. PubMed ID: 6237903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of the in vitro activity of enoxacin on bacterial strains recently isolated in a hospital milieu].
    Lembo M; Nani E; Covelli I; Amato G; Lavitola A
    G Batteriol Virol Immunol; 1985; 78(7-12):205-16. PubMed ID: 3870425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Symposium on antimicrobial agents. The quinolones.
    Walker RC; Wright AJ
    Mayo Clin Proc; 1987 Nov; 62(11):1007-12. PubMed ID: 3312850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
    Chin NX; Novelli A; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):656-62. PubMed ID: 3164987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Corneal and scleral permeability of quinolones--a pharmacokinetics study.
    Tai MC; Lu DW; Chiang CH
    J Ocul Pharmacol Ther; 2003 Dec; 19(6):547-54. PubMed ID: 14733712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antichlamydial activity of quinolone carboxylic acids.
    Heppleston C; Richmond S; Bailey J
    J Antimicrob Chemother; 1985 May; 15(5):645-7. PubMed ID: 3159713
    [No Abstract]   [Full Text] [Related]  

  • 54. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
    Linde HJ; Lehn N
    J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparative in vitro study of the activity of 5 quinolones against Acinetobacter calcoaceticus].
    Joly-Guillou ML; Bergogne-Berezin E
    Pathol Biol (Paris); 1985 May; 33(5):416-20. PubMed ID: 3162142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL; Jones RN
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vibrational spectroscopic characterization of fluoroquinolones.
    Neugebauer U; Szeghalmi A; Schmitt M; Kiefer W; Popp J; Holzgrabe U
    Spectrochim Acta A Mol Biomol Spectrosc; 2005 May; 61(7):1505-17. PubMed ID: 15820884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Heessen FW; Muytjens HL
    Antimicrob Agents Chemother; 1984 Jan; 25(1):123-4. PubMed ID: 6230988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.
    Zweerink MM; Edison A
    Antimicrob Agents Chemother; 1986 Apr; 29(4):598-601. PubMed ID: 3010848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Barry AL; Jones RN; Thornsberry C; Ayers LW; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1984 May; 25(5):633-7. PubMed ID: 6233935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.